Reuters logo
Novartis's canakinumab cut risks for heart attack survivors - study
June 22, 2017 / 5:31 AM / 5 months ago

Novartis's canakinumab cut risks for heart attack survivors - study

ZURICH, June 22 (Reuters) - Novartis’s investigational medicine canakinumab cut cardiovascular risk for people who had survived a heart attack, the Swiss drugmaker said on Thursday, citing a late-stage study.

Canakinumab, also called ACZ885, when used with current standard therapies reduced the risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke in patients with a prior heart attack and inflammatory atherosclerosis, Novartis said. (Reporting by John Miller, editing by Michael Shields)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below